1. No category

Conference Chairs:
Professor
Frank Luyten (Belgium),
Professor
Stefan Lohmander (Sweden),
Professor
Ken Nakata (Japan)
Professor
Ichiro Sekiya (Japan)
6(Thu)-7(Fri)
November
2014
Message
Dear Colleague,
Osteoarthritis (OA) and its treatment remains a challenge in 2014 !
Patient stratification and identifying patients at risk for progression seems imperative to improve the
chances for success. In order to better appreciate and understand outcomes from clinical studies and
new treatments, it appears relevant to improve the characterization of the patient populations with
OA. Therefore, we propose to further contribute to this effort and undertake the challenge to define
early OA of the knee, as we feel there is ample opportunity to make progress paying more attention
to early stages of the disease process. This has already been recognized by our colleagues in Japan
by starting the Japanese Society for Early OA.
In view of the above, we intend to organize the “1st International Early Knee Osteoarthritis
Workshop in Japan”, November 2014.
We envision a 2 day meeting that will focus on defining all aspects of early knee OA, including
epidemiology and patient characteristics, classification criteria, clinical trial design, clinical trial
outcomes, regulatory aspects, research challenges … ..Ideally we would like to leave the meeting
with a consensus on draft classification criteria for early knee OA, defined outcome criteria for
clinical studies, an agenda and strategy for further work at all levels including regulation. We
realize this is very ambitious, but feel it is important to move forward and cross boundaries.
This will be a high level mostly academic small size meeting with a limited number of participants
(100- to max. 150). We may also wish to involve industrial and regulatory partners.
We would very much appreciate if you would join this 1st International Early Knee Osteoarthritis
Workshop in Japan.
Sincerely
Stefan Lohmander, Frank P. Luyten, Ken Nakata, Ichiro Sekiya
Stefan Lohmander
Frank P. Luyten
Ken Nakata
Ichiro Sekiya
1
Organizing Committee
Co-Chairmen
Stefan Lohmander (Sweden)
Frank Luyten (Belgium)
Ken Nakata (Japan)
Ichiro Sekiya (Japan)
Scientific Advisory Board
Amanda Fosang (Australia)
Ana Valdes (UK)
Atsuya Watanabe (Japan)
David Felson (USA)
David Hunter (Australia)
Frank Roemer (Denmark)
Hiroshi Kawaguchi (Japan)
Joanne Jordan (USA)
Johannes Bijlsma (Netherland)
Joseph Buckwalter (USA)
Marc Hochberg (USA)
Michael Doherty (UK)
Michael Nevitt (USA)
Noriko Yoshimura (Japan)
Tonia Vincent (UK)
Virginia Kraus (USA)
Local Committee
Akihiko Yonekura (Japan)
Go Omori (Japan)
Hirotaka Shinjo (Japan)
Hiroyuki Onuma (Japan)
Nobuhiro Abe (Japan)
Soichi Tsuji (Japan)
Tatsuo Mae (Japan)
Tomoyuki Suzuki (Japan)
Yasuyuki Ishibashi (Japan)
2
Facilitator & Speaker
Facilitator
Chian Kent Kwoh (USA)
Francesco Dell`Accio (UK)
Frank Luyten (Belgium)
Hiroshi Kawaguchi (Japan)
Ichiro Sekiya (Japan)
Ken Nakata (Japan)
Naoshi Fukui (Japan)
Nigel Arden (UK)
Sita Bierma-Zeinstra (Netherland)
Stefan Lohmander (Sweden)
Takashi Nishii (Japan)
Yasuyuki Ishibashi (Japan)
Speaker
Carla Scanzello (USA)
Chian Kent Kwoh (USA)
Cosimo DeBari (UK)
Daichi Hayashi (USA)
Frank Luyten (Belgium)
Go Omori (Japan)
Henning Madry (Germany)
Hiroshi Kawaguchi (Japan)
Ichiro Sekiya (Japan)
Martin Englund (Sweden)
Naoshi Fukui (Japan)
Noriko Yoshimura (Japan)
Sita Bierma-Zeinstra (Netherland)
Stefan Lohmander (Sweden)
Susanne Wang (USA)
Virginia Kraus (USA)
Yoko Kobayashi (Japan)
3
Access
TOKYO MARRIOTT HOTEL
4-7-36 Kitashinagawa, Shinagawa-ku, Tokyo 140-0001 Japan
T: 81.3.5488.3911
from Stations
From Shinagawa Station
5 min. by Free Shuttle Bus from both JR &
Keikyu Line Shinagawa Station,
Takanawa Exit / 10min. salk to the hotel.
From Kita-Shinagawa Station
About 5 min. walk from Keikyu Line
Kita-Shinagawa Station.
4
from Airports
From Haneda Airport
Approx. 30 min. by Airport Limousine Bus or
20 min. by Keikyu Line.
From Narita Airport
Approx. 100 min. by Airport Limousine Bus.
Floor Guide
Banquet floor (B1F)
5
Program
November 6 (Thu.)
10:00-10:05
at The GOTENYAMA Ballroom (North)
Welcome
Stefan Lohmander (EU)
Frank Luyten (EU)
10:05-11:45
SESSION 1
Classification criteria for early OA: Why? How?
Facilitators Chian Kent Kwoh (USA)
Hiroshi Kawaguchi (JPN)
Speakers
Virginia Kraus (USA)
Preclinical OA, proposed new standardized definitions
of OA and its stages
Hiroshi Kawaguchi (JPN)
Scientific basis of early OA
Susanne Wang (USA)
Industrial & regulatory perspectives in early OA
Yoko Kobayashi (JPN)
Regulatory perspective in early OA
General discussion with specific list of questions to be addressed
11:50-13:00
SESSION2
Luncheon seminar
sponsored by Teijin Pharma Limited & Sanofi K.K.
Facilitator
Ken Nakata (JPN)
Speaker
Stefan Lohmander (EU)
Ethical considerations in establishing classification criteria
of early OA: patient, caregivers, and payers
6
at The GOTENYAMA Ballroom (North)
13:00-14:30
SESSION 3
Clinical signs and symptoms in early OA
Facilitators Ken Nakata (JPN)
Sita Bierma-Zeinstra (EU)
Speakers
Sita Bierma-Zeinstra (EU)
Pain, symptoms and signs
Frank Luyten (EU)
Function
Breakout session
Consolidation
14:30-15:00
15:00-16:45
Coffee & Tea Break
SESSION 4
Structural features of early OA
Facilitators Nigel Arden (EU)
Ichiro Sekiya (JPN)
Speakers
Noriko Yoshimura (JPN)
Radiographs: What features and criteria to use?
Chian Kent Kwoh (USA)
Radiographs: Do we need them for diagnosis and
prognosis of early OA?
Go Omori (JPN)
Arthroscopy: is it useful? What criteria to use?
Diagnosis and prognosis?
Breakout session
Consolidation
7
at The GOTENYAMA Ballroom (South)
16:45-17:05
17:05-18:15
Welcome reception
SESSION 5
Evening Seminar: Pathophysiology of early OA
sponsored by Protea Japan Co., Ltd.
Facilitator
Frank Luyten (EU)
Speakers
Carla Scanzello (USA)
Inflammation and early OA
Henning Madry (EU)
Cartilage/subchondral bone, meniscus and biomechanics
in early OA
General discussion
18:30
8
Conference dinner
Memo
9
November 7 (Fri.)
7:20-8:30
at The GOTENYAMA Ballroom (North)
SESSION 6
Breakfast seminar: Biomarkers in early OA
sponsored by ReasonWhy Inc.
Facilitators Francesco Dell`Accio (EU)
Naoshi Fukui (JPN)
Speakers
Virginia Krauss (USA)
Biomarkers: which, when...
Naoshi Fukui (JPN)
Biomarkers in early OA
Break out session
Consolidation
8:30-10:30
SESSION 7
MRI features of early OA
Facilitators Stefan Lohmander (EU)
Takashi Nishii (JPN)
Speakers
Martin Englund (EU)
MRI: methodology, what can we score, scoring systems,
level of standardization? Diagnosis and prediction?
Daichi Hayashi (USA)
Advances (qualitative, quantitative, 3D assessment)
in MRI relevant to early OA
Takashi Nishii (JPN)
Advances (dynamic, quantitative, 3D assessment)
in MRI relevant to early OA
Breakout session
Consolidation
10
at The GOTENYAMA Ballroom (North)
10:30-10:50
10:50-11:50
Coffee & Tea Break
SESSION 8
Towards criteria and classification of early OA
Facilitators Frank Luyten (EU)
Stefan Lohmander (EU)
Plenary discussion of first draft of criteria
Clinical, imaging, biomarkers, study design.....
11:50-13:00
SESSION 9
Luncheon seminar: New therapies in the pipeline
sponsored by Taisho Toyama Pharmaceutical Co.,Ltd
Facilitators Chian Kent Kwoh (USA)
Yasuyuki Ishibashi (JPN)
Speakers
Cosimo DeBari (EU)
Stem cell technology and early OA
Ichiro Sekiya (JPN)
Novel therapies in early OA
General discussion
13:00
Closing of the workshop
Ken Nakata (JPN)
Ichiro Sekiya (JPN)
11
Memo
12
Sponsorship
Main Sponsor
OARSI Osteoarthritis Research Society International
Teijin Pharma Limited
Diamond Contributor
Taisho Toyama Pharmaceutical Co., Ltd.
Protea Japan Co., Ltd.
ReasonWhy Inc.
Sanofi K.K.
Japan Tissue Engineering Co., Ltd.
Platinum Contributor
Alcare Co., Ltd.
Biomet Japan, Inc.
Flexion Therapeutics
Nippon Sigmax Co., Ltd.
Olympus Termo Biomaterials Corp.
Olympus-rms Corp.
Pfizer Japan Inc.
Shilac Japan, Inc.
Smith & Nephew Endoscopy KK
Stryker Japan K.K.
Technogym Japan, Ltd.
Gold Contributor
Arthrex Japan Co., Ltd.
Astellas Pharma Inc.
Chugai Pharmaceutical Co., Ltd.
Cytori Therapeutics KK
Denki Kagaku Kogyo Kabushiki Kaisha
Eli Lilly Japan K.K.
Hisamitsu Pharmaceutical Co., Ltd.
Iso Medical Systems Inc.
Kaken Pharmaceutical Co., Ltd.
Kawamura Gishi Co., Ltd.
Meira Corporation
MicroPort Orthopedics Japan K.K.
Mikasa Seiyaku Co., Ltd.
MSD K.K.
Two Cells Co., Ltd.
Zimmer K.K.
13
0910_スミルスチック_A5Y
フェルビナク固形軟膏
経皮吸収型鎮痛・消炎剤
薬価基準収載
製造販売元
〔資料請求先〕
〒１７６－８５８５
東 京 都 練 馬 区 豊 玉 北２－３－１
フェルビナク固形軟膏
http://www.mikasaseiyaku.co.jp/
●「効能・効果」、
「用法・用量」、
「禁忌を含む使用上の注意」等については添付文書をご参照ください。
ISO 9001
ISO 14001
JQA-QM9235 三笠製薬株式会社
JQA-EM0987 三笠製薬掛川工場
２００９年１１月作成
セルーション 遠心分離器
セルーション遠心分離器は
脂肪組織由来再生(幹)細胞(ADRCs*1)
を自動化されたシステムにより
安定的に分離する装置です
• 平均処理時間　90分*2
• 脂肪組織処理量 100mL ~ 360mL
• 最終分離細胞量 5mL*3
*1 Adipose-Derived Stem and Regenerative Cells
*2 処理時間は処理量により変動します
*3 細胞量：脂肪組織100mL当たり　25,000,000~40,000,000個
販売名
セルーション 遠心分離器
一般的名称
細胞用遠心機
医療機器製造販売届出番号
13B1X10155000001
サイトリ・セラピューティクス株式会社
〒105-0004 東京都港区新橋6-17-21住友不動産御成門駅前ビル11F
03-6870-7500
www.cytori.com/ja/home.aspx
第一種医療機器製造販売業
13B1X10155
器
)
ル11F
.aspx